ANDRX ANNOUNCES FILING OF NDA BY TAKEDA FOR ACTOS

A A

Andrx Corporation announced today that Takeda Global Research & Development Center Inc. filed a New Drug Application (NDA) for a combination product consisting of Takeda's ACTOS (pioglitazone HCl) and Andrx's extended-release metformin to the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=100849)